University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research.
University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Genetics.
Int J Med Sci. 2018 Jan 1;15(1):36-45. doi: 10.7150/ijms.21666. eCollection 2018.
Results obtained from completed and on-going clinical studies indicate huge therapeutic potential of stem cell-based therapy in the treatment of degenerative, autoimmune and genetic disorders. However, clinical application of stem cells raises numerous ethical and safety concerns. In this review, we provide an overview of the most important ethical issues in stem cell therapy, as a contribution to the controversial debate about their clinical usage in regenerative and transplantation medicine. We describe ethical challenges regarding human embryonic stem cell (hESC) research, emphasizing that ethical dilemma involving the destruction of a human embryo is a major factor that may have limited the development of hESC-based clinical therapies. With previous derivation of induced pluripotent stem cells (iPSCs) this problem has been overcome, however current perspectives regarding clinical translation of iPSCs still remain. Unlimited differentiation potential of iPSCs which can be used in human reproductive cloning, as a risk for generation of genetically engineered human embryos and human-animal chimeras, is major ethical issue, while undesired differentiation and malignant transformation are major safety issues. Although clinical application of mesenchymal stem cells (MSCs) has shown beneficial effects in the therapy of autoimmune and chronic inflammatory diseases, the ability to promote tumor growth and metastasis and overestimated therapeutic potential of MSCs still provide concerns for the field of regenerative medicine. This review offers stem cell scientists, clinicians and patient's useful information and could be used as a starting point for more in-depth analysis of ethical and safety issues related to clinical application of stem cells.
已完成和正在进行的临床研究结果表明,基于干细胞的疗法在治疗退行性、自身免疫性和遗传性疾病方面具有巨大的治疗潜力。然而,干细胞的临床应用引发了许多伦理和安全问题。在这篇综述中,我们概述了干细胞治疗中最重要的伦理问题,为关于其在再生和移植医学中的临床应用的有争议的辩论做出了贡献。我们描述了涉及人胚胎干细胞 (hESC) 研究的伦理挑战,强调涉及人类胚胎破坏的伦理困境是限制 hESC 为基础的临床治疗发展的主要因素。随着以前诱导多能干细胞 (iPSC) 的衍生,这个问题已经得到解决,但是目前关于 iPSC 的临床转化的观点仍然存在。iPSC 的无限分化潜力可用于人类生殖性克隆,这是产生基因工程人类胚胎和人-动物嵌合体的主要风险,而不受控制的分化和恶性转化是主要的安全问题。尽管间充质干细胞 (MSC) 的临床应用在自身免疫性和慢性炎症性疾病的治疗中显示出有益的效果,但促进肿瘤生长和转移以及对 MSC 治疗潜力的高估仍然是再生医学领域关注的问题。这篇综述为干细胞科学家、临床医生和患者提供了有用的信息,并可以作为进一步分析与干细胞临床应用相关的伦理和安全问题的起点。